Esophagus to Small Intestine

Gut. 2022;71(6):1088–94

Bergman D, King J, Lebwohl B, Clements MS, Roelstraete B, Kaplan GG, Green PHR, Murray JA, Ludvigsson JF

Two waves of celiac disease incidence in Sweden: A nationwide population-based cohort study from 1990 to 2015

Objectives: To assess the incidence of biopsy-verified celiac disease (CD) in Sweden and examine the incidence of duodenal/jejunal biopsies with normal mucosa over time as a proxy for CD awareness and investigation.
Design: Nationwide population-based cohort study 1990–2015 based on biopsy reports indicating villous atrophy (VA) or normal mucosa in the duodenum/jejunum.
Results: The authors identified 44,771 individuals (63% females) with a biopsy report specifying VA and 412,279 (62% females) with a biopsy report indicating normal mucosa (without a prior biopsy indicating VA). The median age at diagnosis of CD was 28 years. The mean age-standardized incidence rate during the study period was 19.0 per 100,000 person-years (95% confidence interval: 17.3–20.8). The incidence reached a peak in 1994 for both sexes and a second higher peak in 2002–2003 for females and in 2006 for males. The lifetime risk of developing CD was 1.8% (2.3% in females and 1.4% in males). Prior to 2015, there was a parallel rise in rates for biopsies showing normal duodenal/jejunal mucosa.

Conclusions: In Sweden, the incidence of celiac disease (CD) increased until 2002–2003 in females and until 2006 in males. Since then, the incidence of CD has declined despite increasing duodenal/jejunal biopsies, suggesting that increased awareness and investigation are unlikely to elevate the incidence of the disease in Sweden. Across a lifetime, 1 in 44 females and 1 in 72 males are expected to be diagnosed with CD in Sweden, indicating a relatively high societal burden of disease.

Dr. D. Bergman, Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden,

DOI: DOI: 10.1136/gutjnl-2021-324209

Back to overview

this could be of interest:

Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: Results from a randomized, sham-controlled trial

Gut. 2022;71(4):686–94

Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): An open-label, multicenter, randomized phase 3b trial

Lancet Gastroenterol Hepatol. 2022;7(4):294–306

More articles on the topic